HRP20161261T1 - Derivati nitrokatehola kao comt inhibori primijenjeni prema specifičnom režimu doziranja - Google Patents
Derivati nitrokatehola kao comt inhibori primijenjeni prema specifičnom režimu doziranja Download PDFInfo
- Publication number
- HRP20161261T1 HRP20161261T1 HRP20161261TT HRP20161261T HRP20161261T1 HR P20161261 T1 HRP20161261 T1 HR P20161261T1 HR P20161261T T HRP20161261T T HR P20161261TT HR P20161261 T HRP20161261 T HR P20161261T HR P20161261 T1 HRP20161261 T1 HR P20161261T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- preparation according
- preparation
- group
- Prior art date
Links
- YHKWFDPEASWKFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1O YHKWFDPEASWKFQ-UHFFFAOYSA-N 0.000 title 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 7
- ASOADIZOVZTJSR-UHFFFAOYSA-N opicapone Chemical compound CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C1=NOC(C=2C=C(C(O)=C(O)C=2)[N+]([O-])=O)=N1 ASOADIZOVZTJSR-UHFFFAOYSA-N 0.000 claims 6
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 claims 3
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 claims 3
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 3
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003435 aroyl group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
- 229960000911 benserazide Drugs 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000011630 iodine Chemical group 0.000 claims 1
- 229910052740 iodine Chemical group 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 125000005000 thioaryl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (18)
1. Farmaceutski pripravak koji sadrži spoj formule I
[image]
gdje su R1 i R2 vodik; X označava metilensku skupinu; Y predstavlja atom kisika ili sumpora; n predstavlja broj 0, 1, 2 ili 3 i m predstavlja broj 0 ili 1; R3 označava piridin N-oksid skupinu prema formuli A, B, ili C, a koja je spojena na mjestu neoznačene veze:
[image]
gdje su R4, R5, R6 i R7 isti ili različiti i označavaju vodik, C1-C6 alkil, C1-C6 tioalkil, C1-C6 alkoksi, ariloksi ili tioaril skupinu, C1-C6 alkanoil ili aroil skupinu, po izobru supstituiranu aril skupinu, amino, C1-C6 alkilamino, C1-C6 dialkilamino cikloalkilamino ili heterocikloalkilamino skupinu, C1-C6 alkilsulfonil ili arilsulfonil skupinu, halogen, haloalkil, trifluorometil, cijano, nitro ili heteroaril skupinu, ili uzeti zajedno predstavljaju alifatske ili heteroalifatske prstenove ili aromatske ili heteroaromatske prstenove; pojam alkil znači ugljikove lance, ravne ili razgranate, s jednim do šest atoma ugljika; pojam aril znači fenil ili naftil skupinu, po izobru supstituiranu s alkoksi ili halogen skupinama; pojam heterocikloalkil predstavlja četvero- do osmeročlani ciklički prsten koji po izboru obuhvaća druge atome kisika, sumpora ili dušika; pojam heteroaril predstavlja pet- do šesteročlani prsten koji obuhvaća atom sumpora, kisika ili dušika; pojam halogen predstavlja fluor, klor, brom ili jod; ili njegovu farmaceutski prikladnu sol, a taj farmaceutski pripravak je jedinični dozirni oblik koji sadrži 1 do 500 mg tog spoja ili soli.
2. Pripravak prema zahtjevu 1 koji sadrži 2 do 300 mg spoja formule I ili njegove farmaceutski prikladne soli.
3. Pripravak prema zahtjevu 1 koji sadrži 3 do 100 mg spoja formule I ili njegove farmaceutski prikladne soli.
4. Pripravak prema zahtjevu 1 koji sadrži 5 do 50 mg spoja formule I ili njegove farmaceutski prikladne soli.
5. Pripravak prema zahtjevu 1 koji sadrži 5 mg spoja formule I ili njegove farmaceutski prikladne soli.
6. Pripravak prema zahtjevu 1 koji sadrži 50 mg spoja formule I ili njegove farmaceutski prikladne soli.
7. Pripravak prema zahtjevu 1 gdje je spoj formule I 5-[3-(2,5-dikloro-4,6-dimetil-1-oksipiridin-3-il)-[1,2,4]-oksadiazol-5-il]-3-nitrobenzen-1,2-diol.
8. Pripravak prema zahtjevu 2 gdje je spoj formule I 5-[3-(2,5-dikloro-4,6-dimetil-1-oksipiridin-3-il)-[1,2,4]-oksadiazol-5-il]-3-nitrobenzen-1,2-diol.
9. Pripravak prema zahtjevu 3 gdje je spoj formule I 5-[3-(2,5-dikloro-4,6-dimetil-1-oksipiridin-3-il)-[1,2,4]-oksadiazol-5-il]-3-nitrobenzen-1,2-diol.
10. Pripravak prema zahtjevu 4 gdje je spoj formule I 5-[3-(2,5-dikloro-4,6-dimetil-1-oksipiridin-3-il)-[1,2,4]-oksadiazol-5-il]-3-nitrobenzen-1,2-diol.
11. Pripravak prema zahtjevu 5 gdje je spoj formule I 5-[3-(2,5-dikloro-4,6-dimetil-1-oksipiridin-3-il)-[1,2,4]-oksadiazol-5-il]-3-nitrobenzen-1,2-diol.
12. Pripravak prema zahtjevu 6 gdje je spoj formule I 5-[3-(2,5-dikloro-4,6-dimetil-1-oksipiridin-3-il)-[1,2,4]-oksadiazol-5-il]-3-nitrobenzen-1,2-diol.
13. Pripravak prema bilo kojem od zahtjeva 1 do 12 za uporabu u liječenju Parkinsonove bolesti.
14. Pripravak za uporabu prema zahtjevu 13 za uporabu u liječenju bolesnika liječenog s L-DOPA i inhibitorom dekarboksilaze aromatske L-aminokiseline.
15. Pripravak za uporabu prema zahtjevu 14 gdje je spoj kako je definiran u zahtjevu 10.
16. Pripravak za uporabu prema zahtjevu 14 ili zahtjevu 15, gdje je inhibitor dekarboksilaze aromatske L-aminokiseline karbidopa ili benzerazid.
17. Pakiranje koji sadrži pripravak prema bilo kojem od zahtjeva 1 do 12 u kombinaciji s uputama za primjenu pripravka s režimom doziranja takvim da je periodičnost doziranja u rasponu od dva puta dnevno do jednom svaki drugi dan.
18. Pakiranje prema zahtjevu 17, gdje pakiranje dalji sadrži L-DOPA i/ili inhibitor dekarboksilaze aromatske L-aminokiseline.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07002091 | 2007-01-31 | ||
| EP12163797.9A EP2481410B1 (en) | 2007-01-31 | 2007-10-10 | Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20161261T1 true HRP20161261T1 (hr) | 2016-12-02 |
| HRP20161261T8 HRP20161261T8 (hr) | 2016-12-30 |
Family
ID=38961862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161261TT HRP20161261T8 (hr) | 2007-01-31 | 2016-10-03 | Derivati nitrokatehola kao comt inhibitori primijenjeni prema specifičnom režimu doziranja |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8524746B2 (hr) |
| EP (2) | EP2481410B1 (hr) |
| JP (1) | JP5517629B2 (hr) |
| KR (1) | KR101522157B1 (hr) |
| CN (1) | CN101631548B (hr) |
| AR (2) | AR065098A1 (hr) |
| AU (1) | AU2007346018A1 (hr) |
| BR (1) | BRPI0721213B1 (hr) |
| CA (1) | CA2678391C (hr) |
| CY (1) | CY1118311T1 (hr) |
| DK (2) | DK2124947T3 (hr) |
| ES (2) | ES2644049T3 (hr) |
| HR (1) | HRP20161261T8 (hr) |
| HU (1) | HUE031317T2 (hr) |
| IL (1) | IL200020A (hr) |
| LT (1) | LT2481410T (hr) |
| MX (1) | MX2009008051A (hr) |
| NO (1) | NO20092905L (hr) |
| PL (1) | PL2481410T3 (hr) |
| PT (2) | PT2481410T (hr) |
| RU (1) | RU2518483C2 (hr) |
| SI (1) | SI2481410T1 (hr) |
| WO (1) | WO2008094053A1 (hr) |
| ZA (1) | ZA200905940B (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL169855A (en) * | 2005-07-25 | 2014-05-28 | Elta Systems Ltd | A system and method for locating a receiver location |
| KR101370280B1 (ko) | 2005-07-26 | 2014-03-06 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Ｃｏｍｔ 억제제로서의 니트로카테콜 유도체 |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| MX2009006304A (es) | 2006-12-15 | 2009-06-23 | Abbott Lab | Nuevos compuestos de oxadiazol. |
| HUE031317T2 (hu) | 2007-01-31 | 2017-07-28 | Bial - Portela & Ca S A | Specifikus dózisprotokollal adagolt COMT inhibitor nitrokatechin származékok |
| AU2009217865A1 (en) * | 2008-02-28 | 2009-09-03 | Bial - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| AU2009226221A1 (en) * | 2008-03-17 | 2009-09-24 | Bial - Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| US20110301204A1 (en) * | 2008-07-29 | 2011-12-08 | Bial - Portela & Ca., S.A. | Administration regime for nitrocatechols |
| KR102329271B1 (ko) * | 2009-04-01 | 2021-11-22 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| MX361618B (es) * | 2009-04-01 | 2018-12-13 | Bial Portela & Ca Sa | Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas. |
| US8598235B2 (en) | 2009-12-04 | 2013-12-03 | Jon E. Grant | Treating impulse control disorders with catechol-O-methyl-transferase inhibitors |
| US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PL2791134T3 (pl) * | 2011-12-13 | 2020-03-31 | BIAL - PORTELA & Cª S.A. | Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy |
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| US9951057B2 (en) | 2015-01-30 | 2018-04-24 | Lieber Institute For Brain Development | COMT inhibiting methods and compositions |
| CA2975398C (en) | 2015-01-30 | 2023-02-21 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
| ES2893613T3 (es) | 2015-11-25 | 2022-02-09 | Lieber Inst Inc Dba Lieber Inst For Brain Development | Tetrahidro-8H-pirido[1,2-a]pirazin-8-onas como inhibidores de COMT para el tratamiento de trastornos neurodegenerativos |
| CA3112994A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| US20210338651A1 (en) | 2018-10-05 | 2021-11-04 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| USD912395S1 (en) * | 2019-11-01 | 2021-03-09 | Jondarius Brown | Apparatus for storing earphones |
| GB202204798D0 (en) | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US660753A (en) * | 1899-11-27 | 1900-10-30 | Ferdinand-Christoph Von Heydebrand Und Der Lasa | Artificial fuel. |
| US1532178A (en) | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
| US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
| EP0462639A1 (en) | 1990-06-05 | 1991-12-27 | Shell Internationale Researchmaatschappij B.V. | Preparation of 2-chloropyridine derivatives |
| DE69013689T2 (de) | 1990-11-29 | 1995-03-02 | Wei Ming Pharmaceutical Mfg Co | Hilfsträger für direkte Verpressung. |
| CA2126976A1 (en) | 1991-12-31 | 1993-07-08 | Hisashi Takasugi | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| GB9419274D0 (en) * | 1994-09-23 | 1994-11-09 | Orion Yhtymae Oy | New method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde |
| DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| US6206110B1 (en) | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| ES2250177T3 (es) | 1999-08-19 | 2006-04-16 | Nps Pharmaceuticals, Inc. | Compuestos heteropoliciclicos y su uso como antagonistas de receptores de glutamato metabotropico. |
| FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| GB2363792A (en) * | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
| WO2002017175A1 (fr) | 2000-08-24 | 2002-02-28 | Sagawa Express Co., Ltd. | Procede de paiement par carte pour facturation de service concernant une distribution ou un transport physiques |
| CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
| JP2004532611A (ja) | 2000-11-28 | 2004-10-28 | ザイモジェネティクス，インコーポレイティド | サイトカイン受容体ｚｃｙｔｏｒ１９ |
| US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| CA2436739A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Combination agent |
| IL157491A0 (en) | 2001-02-21 | 2004-03-28 | Nps Pharmeceuticals Inc | Heteropolycyclic compounds and pharmaceutical compositions containing the same |
| JP2004534779A (ja) | 2001-05-30 | 2004-11-18 | エルジー ライフサイエンス リミテッド | 疾病治療用プロテインキナーゼ阻害剤 |
| CN1638776A (zh) | 2001-06-08 | 2005-07-13 | 西托维亚公司 | 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物 |
| DK1408964T3 (da) | 2001-07-26 | 2007-05-21 | Merck Patent Gmbh | Hidtil ukendt anvendelse af 2-5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman og fysiologisk acceptable salte deraf |
| JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
| EP1581213A4 (en) | 2002-12-18 | 2008-11-19 | Cytovia Inc | 3,5-DISUBSTITUES-1,2,4-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND APOPTOSIS PROMOTERS, AND USE THEREOF |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| EP1663211B1 (en) | 2003-08-06 | 2010-01-20 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| DE602005020611D1 (de) | 2004-04-28 | 2010-05-27 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2006051154A1 (en) | 2004-11-10 | 2006-05-18 | Orion Corporation | Treatment of restless legs syndrome |
| WO2006061697A1 (en) | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
| EP1833804A1 (en) | 2004-12-28 | 2007-09-19 | AstraZeneca AB | Aryl sulphonamide modulators |
| US20080051441A1 (en) | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| MX2007013263A (es) | 2005-04-26 | 2008-01-22 | Neurosearch As | Novedosos derivados oxadiazol y su uso medico. |
| US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| US7553964B2 (en) | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
| JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
| KR101370280B1 (ko) | 2005-07-26 | 2014-03-06 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Ｃｏｍｔ 억제제로서의 니트로카테콜 유도체 |
| GB0515327D0 (en) * | 2005-07-26 | 2005-08-31 | Portela & Ca Sa | Comt inhibitors |
| FR2889525A1 (fr) | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
| US20070048384A1 (en) | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| EP1954137A4 (en) | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| EP1956013B1 (en) | 2005-11-30 | 2016-04-13 | Fujifilm RI Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| HUE031317T2 (hu) | 2007-01-31 | 2017-07-28 | Bial - Portela & Ca S A | Specifikus dózisprotokollal adagolt COMT inhibitor nitrokatechin származékok |
| MX2010002258A (es) | 2007-08-27 | 2010-04-22 | Helicon Therapeutics Inc | Compuestos terapeuticos de isoxazol. |
| AU2009217865A1 (en) | 2008-02-28 | 2009-09-03 | Bial - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| AU2009226221A1 (en) | 2008-03-17 | 2009-09-24 | Bial - Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| US20110301204A1 (en) | 2008-07-29 | 2011-12-08 | Bial - Portela & Ca., S.A. | Administration regime for nitrocatechols |
| KR102329271B1 (ko) | 2009-04-01 | 2021-11-22 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| MX361618B (es) | 2009-04-01 | 2018-12-13 | Bial Portela & Ca Sa | Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas. |
| KR101868326B1 (ko) | 2010-03-04 | 2018-06-19 | 오리온 코포레이션 | 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PL2791134T3 (pl) | 2011-12-13 | 2020-03-31 | BIAL - PORTELA & Cª S.A. | Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy |
-
2007
- 2007-10-10 HU HUE12163797A patent/HUE031317T2/hu unknown
- 2007-10-10 PT PT121637979T patent/PT2481410T/pt unknown
- 2007-10-10 CA CA2678391A patent/CA2678391C/en active Active
- 2007-10-10 PT PT78349115T patent/PT2124947T/pt unknown
- 2007-10-10 MX MX2009008051A patent/MX2009008051A/es active IP Right Grant
- 2007-10-10 BR BRPI0721213-5A patent/BRPI0721213B1/pt active IP Right Grant
- 2007-10-10 US US12/524,848 patent/US8524746B2/en active Active
- 2007-10-10 LT LTEP12163797.9T patent/LT2481410T/lt unknown
- 2007-10-10 WO PCT/PT2007/000043 patent/WO2008094053A1/en active Application Filing
- 2007-10-10 CN CN200780050737.2A patent/CN101631548B/zh active Active
- 2007-10-10 SI SI200731839A patent/SI2481410T1/sl unknown
- 2007-10-10 EP EP12163797.9A patent/EP2481410B1/en active Active
- 2007-10-10 AU AU2007346018A patent/AU2007346018A1/en not_active Abandoned
- 2007-10-10 ES ES07834911.5T patent/ES2644049T3/es active Active
- 2007-10-10 DK DK07834911.5T patent/DK2124947T3/da active
- 2007-10-10 RU RU2009132188/04A patent/RU2518483C2/ru active
- 2007-10-10 EP EP07834911.5A patent/EP2124947B1/en active Active
- 2007-10-10 JP JP2009548186A patent/JP5517629B2/ja active Active
- 2007-10-10 DK DK12163797.9T patent/DK2481410T3/en active
- 2007-10-10 KR KR1020097016752A patent/KR101522157B1/ko active IP Right Review Request
- 2007-10-10 PL PL12163797T patent/PL2481410T3/pl unknown
- 2007-10-10 ES ES12163797.9T patent/ES2597705T3/es active Active
-
2008
- 2008-01-30 AR ARP080100382A patent/AR065098A1/es not_active Application Discontinuation
-
2009
- 2009-07-22 IL IL200020A patent/IL200020A/en active IP Right Grant
- 2009-08-27 ZA ZA200905940A patent/ZA200905940B/xx unknown
- 2009-08-28 NO NO20092905A patent/NO20092905L/no not_active Application Discontinuation
-
2013
- 2013-07-25 US US13/950,661 patent/US20130331416A1/en not_active Abandoned
-
2015
- 2015-04-17 US US14/689,397 patent/US9745290B2/en active Active
-
2016
- 2016-10-03 HR HRP20161261TT patent/HRP20161261T8/hr unknown
- 2016-10-12 CY CY20161101012T patent/CY1118311T1/el unknown
-
2017
- 2017-09-08 AR ARP170102484A patent/AR109590A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161261T1 (hr) | Derivati nitrokatehola kao comt inhibori primijenjeni prema specifičnom režimu doziranja | |
| MA42232B1 (fr) | Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| HRP20160967T1 (hr) | Heterociklički spojevi korisni kao pdk1 inhibitori | |
| JP2011500506A5 (hr) | ||
| RU2010154173A (ru) | Режим введения нитрокатехолов | |
| HRP20220339T1 (hr) | Antibakterijski spojevi | |
| AR055916A1 (es) | Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica | |
| HRP20080184T5 (hr) | Azabiciklički derivati, postupak njihove pripravei farmaceutski pripravci koji ih sadrže | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| AR059961A1 (es) | Compuesto derivado de fenil tetrahidro-indazol, composiciones farmaceuticas que lo comprenden, usos para preparar un medicamento para el tratamiento de una enfermedad mediada por una reduccion o desequilibrio en la funcion del receptor de glutamato y procesos para su preparacion | |
| AR044825A1 (es) | Derivados de 5,6-diaril-pirazinas-2-carboxamida y -2-sulfonamidas -3-sustituidas como moduladores de cb1 | |
| EA201001344A1 (ru) | Азотсодержащие бициклические соединения, активные при состояниях хронической боли | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| BR112014016338A2 (pt) | polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos | |
| EA200901146A1 (ru) | Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли | |
| EA201170546A1 (ru) | Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств | |
| MA38854A1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| RU2008129635A (ru) | Ингибиторы ссr9 активности | |
| AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester | |
| HUP0203976A2 (hu) | Adenozin a3 receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| AR060666A1 (es) | Derivados de amina triciclicos que tienen actividad microbicida | |
| WO2006002802A8 (en) | Phenyl derivatives comprising an acetylene group | |
| ATE432262T1 (de) | Pyrazolphenylderivate als ppar-aktivatoren | |
| AR065419A1 (es) | Metodo para inhibir la proliferacion de celulas tumorales |